COVID-19 and Type 2 diabetes Regional experts shed light latest scientific updates and
COVID-19 and Type 2 diabetes: Regional experts shed light on the latest scientific updates and clinical practices in disease management for patient education
Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care
Boehringer Ingelheim hosted the ‘CRM 360 standalone meeting’, ‘IMETA CRM Discussions for EXperts (MEDEX)’, to discuss the latest advances in the management of cardio-renal-metabolic conditions
Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
• Boehringer Ingelheim hosted ‘Heart Talks’and ‘MEDEX’ to discuss latest updates in heart failure management and help improve patient outcomes across India, the Middle East and Africa
Boehringer Ingelheim awarded Top Employer across 29 countries including the UAE, KSA and India
• The Top Employers Institute highlighted Boehringer Ingelheim’s emphasis on wellbeing, attractive work environment, and rewards and recognition when compared with the industry benchmark
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
MORE GREEN: Environmental sustainability at a glance
On Earth Day, we share the progress of our global environmental sustainability MORE GREEN program and what the team is tackling, all 365 days of the year.